Tom 11, Nr 4 (2017)
Wybrane problemy kliniczne
Opublikowany online: 2017-09-18
Wyświetlenia strony
840
Wyświetlenia/pobrania artykułu
3344
Choroby układu sercowo-naczyniowego w grupie pacjentów z POChP lub astmą — o czym warto pamiętać w codziennej praktyce?
Forum Medycyny Rodzinnej 2017;11(4):156-167.
Streszczenie
Choroby układu sercowo-naczyniowego oraz choroby układu oddechowego pozostają główną przyczyną zarówno hospitalizacji, jak i zgonów w Europie. Przewlekła obturacyjna choroba płuc (POChP) i astma zwiększają ryzyko wystąpienia chorób układ krążenia, a przewlekła reakcja zapalana wydaje się być jedną z jego głównych przyczyn. Niektórzy eksperci nazywają wyżej wymienione jednostki chorobowe nieklasycznymi czynnikami ryzyka, o których należy koniecznie pamiętać przy ocenie ryzyka sercowo-naczyniowego pacjentów. Skuteczne leczenie chorób układu sercowo-naczyniowego, jak i astmy oraz POChP, z uwzględnieniem preferowanych grup leków oraz zagrożeń, jakie może nieść ze sobą nieskuteczna farmakoterapia, może się korzystnie przełożyć nie tylko na poprawę kontroli najważniejszych chorób płuc, ale potencjalnie również zmniejszyć ryzyko rozwoju chorób serca i naczyń.
Słowa kluczowe: choroby układu sercowo-naczyniowegoPOChPastma
Referencje
- Townsend N, Wilson L, Bhatnagar P, et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016; 37(42): 3232–3245.
- Chung WS, Shen TC, Lin CL, et al. Adult asthmatics increase the risk of acute coronary syndrome: A nationwide population-based cohort study. Eur J Intern Med. 2014; 25(10): 941–945.
- Onufrak SJ, Abramson JL, Austin HD, et al. Relation of adult-onset asthma to coronary heart disease and stroke. Am J Cardiol. 2008; 101(9): 1247–1252.
- Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012; 379(9823): 1341–1351.
- Mora S, Cook N, Buring JE, et al. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation. 2007; 116(19): 2110–2118.
- Yanbaeva DG, Dentener MA, Creutzberg EC, et al. Systemic effects of smoking. Chest. 2007; 131(5): 1557–1566.
- Broekhuizen R, Wouters EFM, Creutzberg EC, et al. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax. 2006; 61(1): 17–22.
- Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009; 33(5): 1165–1185.
- Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of 'overspill' of inflammatory mediators from the lungs? Review of the evidence. Thorax. 2010; 65(10): 930–936.
- Barnes PJ. Mechanisms in COPD: differences from asthma. Chest. 2000; 117(2 Suppl): 10S–4S.
- Jeffery PK. Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture. Chest. 2000; 117(5 Suppl 1): 251S–60S.
- Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet. 2006; 368(9537): 804–813.
- Phelan PD, Robertson CF, Olinsky A. The Melbourne Asthma Study: 1964-1999. J Allergy Clin Immunol. 2002; 109(2): 189–194.
- Barnes P. Immunology of asthma and chronic obstructive pulmonary disease. Nat Immunol Rev. 2008; 8(3): 183–192.
- Bellocchia M, Masoero M, Ciuffreda A, et al. Predictors of cardiovascular disease in asthma and chronic obstructive pulmonary disease. Multidiscip Respir Med. 2013; 8(1): 58.
- Sexton TR, Wallace EL, Macaulay TE, et al. The effect of rosuvastatin on thromboinflammation in the setting of acute coronary syndrome. J Thromb Thrombolysis. 2015; 39(2): 186–195.
- Gottdiener JS. Intersection of 2 Epidemics: Asthma and Cardiovascular Disease. JACC Heart Fail. 2017; 5(7): 505–506.
- Hiemstra PS, McCray PB, Bals R. The innate immune function of airway epithelial cells in inflammatory lung disease. Eur Respir J. 2015; 45(4): 1150–1162.
- Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000; 35(6): 1628–1637.
- Xu M, Xu J, Yang X. Asthma and Risk of Cardiovascular Disease or All-Cause Mortality: A Meta-Analysis. Ann Saudi Med. 2017; 37(2): 99–105.
- Liu H, Fu Y, Wang K. Asthma and risk of coronary heart disease: A meta-analysis of cohort studies. Ann Allergy Asthma Immunol. 2017; 118(6): 689–695.
- Agusti A, Calverley PMA, Celli B, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010; 11: 122.
- Krahnke JS, Abraham WT, Adamson PB, et al. Champion Trial Study Group. Heart failure and respiratory hospitalizations are reduced in patients with heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure monitoring device. J Card Fail. 2015; 21(3): 240–249.
- Leavitt BJ, Ross CS, Spence B, et al. Northern New England Cardiovascular Disease Study Group. Long-term survival of patients with chronic obstructive pulmonary disease undergoing coronary artery bypass surgery. Circulation. 2006; 114(1 Suppl): I430–I434.
- Mascarenhas J, Lourenço P, Lopes R, et al. Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J. 2008; 155(3): 521–525.
- Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res. 2013; 162(4): 237–251.
- Matamis D, Tsagourias M, Papathanasiou A, et al. Targeting occult heart failure in intensive care unit patients with acute chronic obstructive pulmonary disease exacerbation: effect on outcome and quality of life. J Crit Care. 2014; 29(2): 315.e7–315.14.
- MacDonald MI, Shafuddin E, King PT, et al. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Lancet Respir Med. 2016; 4(2): 138–148.
- Høiseth AD, Neukamm A, Karlsson BD, et al. Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax. 2011; 66(9): 775–781.
- Buch P, Friberg J, Scharling H, et al. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J. 2003; 21(6): 1012–1016.
- Terzano C, Romani S, Conti V, et al. Atrial fibrillation in the acute, hypercapnic exacerbations of COPD. Eur Rev Med Pharmacol Sci. 2014; 18(19): 2908–2917.
- Divo M, Cote C, de Torres JP, et al. BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186(2): 155–161.
- Abusaid GH, Barbagelata A, Tuero E, et al. Diastolic dysfunction and COPD exacerbation. Postgrad Med. 2009; 121(4): 76–81.
- López-Sánchez M, Muñoz-Esquerre M, Huertas D, et al. High Prevalence of Left Ventricle Diastolic Dysfunction in Severe COPD Associated with A Low Exercise Capacity: A Cross-Sectional Study. PLoS One. 2013; 8(6): e68034.
- Campo G, Pavasini R, Biscaglia S, et al. Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease. Eur Heart J Cardiovasc Pharmacother. 2015; 1(3): 205–211.
- Onishi K. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease. J Cardiol. 2017; 70(2): 128–134.
- Cates C, Wieland L, Oleszczuk M, et al. Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2014.
- Worth H, Chung KF, Felser JM, et al. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med. 2011; 105(4): 571–579.
